Risk factors, clinical features, and short-term prognosis of spontaneous fungal peritonitis in cirrhosis: A matched case-control study

doi:10.12998/wjcc.v7.i17.2438

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 17

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5338)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

428

WORD

180

HTML

2288

Figures (1-2)

195

Tables (1-5)

257

Sum=3348

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

695

Download

1295

Sum=1990

Sep 6, 2019 (publication date) through Jun 10, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Sep 6, 2019; 7(17): 2438-2449
Published online Sep 6, 2019. doi: 10.12998/wjcc.v7.i17.2438

Table 1 Comparison of clinical manifestations between spontaneous fungal peritonitis (case) and spontaneous bacteria peritonitis with a positive (control-1) or negative bacterial culture (control-2)

Variable	Case (n = 22)	Control-1 (n = 44)	P-value	Control-2 (n = 72)	P-value
Demographics data
Age (yr), M ± SD	60.0 ± 11.6	58.0 ± 12.5	0.55	56.9 ± 10.5	0.32
Sex (% male)	17 (77.3%)	37 (82.2%)	0.51	55 (74.3%)	1
Current smoking n (%)	7 (31.8%)	20 (45.5%)	0.43	32 (44.4%)	0.33
Alcohol abuse n (%)	7 (31.8%)	16 (36.4%)	0.79	30 (41.3%)	0.46
Aetiology of cirrhosis
Viral n (%)	14 (63.6%)	27 (61.4%)		44 (61.1%)
Alcohol n (%)	2 (9.1%)	8 (18.2%)	0.66	18 (25.0%)	0.334
Others n (%)	6 (27.3%)	9 (20.5%)		13 (18.1%)
Complication
Variceal bleeding n (%)	8 (36.4%)	6 (13.6%)	0.05	18 (25.0%)	0.41
Variceal bleeding n (%)	8 (36.4%)	6 (13.6%)	0.05	18 (25.0%)	0.41
Hepatorenal syndrome n (%)	8 (36.4%)	10 (22.7%)	0.26	9 (12.5%)	0.023
HE n (%)	8 (36.4%)	12 (27.3%)	0.57	14 (19.4%)	0.15
Charlson index (IQR)	4 (3.7-5.0)	4 (3.0-5.0)	0.46	3 (3-5)	0.007
Laboratory examination
WBC, 10⁹ cells/L (IQR)	11.7 (8.2-19.1)	5.6 (2.9-11.2)	0.001	6.2 (4.0-9.5)	<0.001
C-reactive protein, mg/L (IQR)	77.4 (55.9-138.2)	31.4 (14.7-50.6)	<0.001	22.7 (8.9-42.1)	<0.001
Creatinine, μmol/L (IQR)	98.0 (69.5-147.8)	86.0 (60.5-165.0)	0.75	81 (67.0-105.0)	0.228
Albumin, g/dL (M ± SD)	28.1 ± 4.1	26.6±7.5	0.41	29.8 ± 4.9	0.09
Total bilirubin, μmol/L(IQR)	103.5 (27.5-271.5)	85 (34.2-196.5)	0.96	59.5 (30.0-129.0)	0.51
INR (IQR)	1.40 (1.2-2.0)	1.6 (1.3-2.1)	0.37	1.5 (1.3-1.7)	0.56
Ascites PMN (IQR)	2550 (338-4700)	1800 (650-4500)	0.56	550 (302-1375)	0.004
Ascites albumin g/dL (M ± SD)	18.0±8.2	11.4 ± 7.3	0.002	13.1 ± 9.5	0.009
Clinical presentation
Abdominal pain	7 (31.8%)	17 (38.6%)	0.79	17 (23.6%)	0.578
Fever (T ≥ 38°C)	12 (54.5%)	22 (50.0%)	0.79	19 (26.4%)	0.02
Antibiotic treatment before peritonitis (d)	15.4 (3.8-24.8)	2 (0.3-10.0)	0.001	2 (0-8.0)	<0.001
PPI administration	8 (36.4%)	27 (61.4%)	0.07	43(59.7%)	0.086
Nosocomial infection	13 (59.1%)	30 (68.2%)	0.59	44 (61.1%)	1
ICU admission	1 (4.5%)	2 (4.5%)	1	1 (1.4%)	0.42
Septic shock n (%)	7 (31.8%)	8 (18.2%)	0.23	3 (4.2%)	0.001
SIRS n (%)	14 (63.6%)	20 (45.5%)	0.2	14 (19.4%)	<0.001
Concomitant bacterial infection	12 (54.5%)	13 (29.5%)	0.12	3 (4.2%)	<0.001
Blood infection	6 (27.2%)	9 (20.5%)	1	1 (1.4%)	<0.001
Pneumonia	3 (13.6%)	3 (6.8%)	0.39	2 (2.8%)	0.048
Bacterial peritonitis	9 (40.9%)	-	-	-	-
Other sites	1 (4.5%)	1 (2.3%)	-	1 (1.4%)	-
Severity score
SOFA (M ± SD)	7.1 ± 3.8	7.6 ± 4.7	0.65	5.2 ± 2.6	0.035
CLIF-SOFA	7.1 ± 3.4	8.1 ± 4.4	0.33	5.6 ± 3.0	0.048
APACHE II	7.6 ± 6.1	6.7 ± 5.4	0.58	3.0 ± 3.1	<0.001
MELD (IQR)	15.9 (7.5-25.2)	18.3 (9.3-25.9)	0.76	14.6 (9.7-20.3)	0.57
MELD-Na (IQR)	23.0 (10.4-35.1)	20.4 (9.7-31.1)	0.88	15.5 (10.1-25.0)	0.17
CTP (IQR)	11.0 (8-12.3)	11.5 (10.0-12.0)	0.39	10 (9.0-12.0)	0.48
15-d mortality	10 (45.1%)	9 (20.4%)	0.046	5 (6.9%)	<0.001

M: Mean; SD: Standard deviation; IQR: Interquartile range; HE: Hepatic encephalopathy; INR: International normalized rate; PMN: Polymorphonuclear neutrophil; ICU: Intensive care unit; PPI: Proton pump inhibitor; SIRS: Systemic inflammatory response; SOFA: Sequential organ failure assessment; CLIF-SOFA: Chronic liver failure-sequential organ failure assessment; APACHE II: Chronic liver failure-sequential organ failure assessment; MELD: Model for end-stage liver disease; CTP: Child-Turcotte-Pugh.

Table 2 Comparison of clinical manifestations between spontaneous fungal peritonitis and fungiascites

Variable	Total (n = 35)	SFP (n = 22)	Fungiascites (n = 13)	P-value
Antibiotic treatment before peritonitis (d)	12 (5.0-23.0)	15.4 (3.8-24.8)	12.0 (6.0-22.0)	0.8
Anti-fungal therapy	15 (42.9%)	8 (36.4%)	7 (53.8%)	0.48
Septic shock n (%)	8 (22.9%)	7 (31.8%)	1 (4.2%)	0.21
WBC, 10⁹ cells/L (IQR)	9.4 (5.6-18.1)	11.7 (8.2-19.1)	6.8 (3.6-12.0)	0.046
C-reactive protein, mg/L (IQR)	69.0 (33.3-110.5)	77.4 (55.9-138.2)	36.6 (13.4-72.1)	0.01
SIRS n (%)	19 (54.3%)	14 (63.6%)	5 (38.5%)	0.18
Fungus
Candida spp.	26 (74.2%)	18 (81.8%)	8 (61.5%)	-
Trichosporon	2 (5.7%)	1 (4.5%)	1 (7.6%)	-
Aspergillus	5 (14.3%)	3 (13.6%)	2 (15.3%)	-
Cryptococcus laurentii	2 (5.7%)	0 (0%)	2 (15.3%)	-
Severity score
SOFA (M ± SD)	6.8 ± 3.5	7.1 ± 3.8	5.2 ± 2.6	0.77
MELD (IQR)	14.7 (8.0-24.3)	15.9 (7.5-25.2)	14.2 (8.8-24.8)	0.92
CTP (IQR)	11.0 (9.0-12.0)	11.0 (8.0-12.3)	11.0 (9.0-11.5)	0.7
15-d mortality	13 (37.1%)	10 (45.1%)	3 (23.7%)	0.28

M: Mean; SD: Standard deviation; IQR: Interquartile range; SOFA: Sequential organ failure assessment; MELD: Model for end-stage liver disease; CTP: Child-Turcotte-Pugh.

Table 3 Risk factors for spontaneous fungal peritonitis as determined by univariate logistic regression analysis

Variable	Control-1 group (n = 44) vs Case group (n = 22)		Control-2 (n = 72) vs Case group (n = 22)
Variable	OR (95%CI)	P-value	OR (95%CI)	P-value
Variceal bleeding	3.619 (1.065-12.296)	0.039	1.71 (0.619-4.751)	0.3
Hepatorenal syndrome	1.943 (0.635-5.947)	0.245	4.00 (1.312-12.194)	0.015
HE	1.524 (0.511-4.546)	0.45	2.367 (0.831-6.742)	0.107
Charlson index	0.936 (0.682-1.284)	0.681	1.266 (0.911-1.759)	0.16
chemoradiotherapy	2.048 (0.122-34.370)	0.618	3.381 (0.203-56.396)	0.396
Alcohol abuse	0.817 (0.275-2.422)	0.715	0.657 (0.237-1.798)	0.41
Length of hospital stay (d)	0.974 (0.944-1.004)	0.092	0.997 (0.969-1.035)	0.874
Antibiotic treatment before diagnosis (d)	1.063 (1.012-1.115)	0.014	1.054 (1.014-1.096)	0.008
PPI administration	0.436 (0.153-1.239)	0.119	0.467 (0.177-1.234)	0.124
Child C grade	0.551 (0.173-1.755)	0.313	1.211 (0.438-3.352)	0.712
MELD score	0.988 (0.942-1.035)	0.603	1.025 (0.970-1.083)	0.38

HE: Hepatic encephalopathy; PPI: Proton pump inhibitor; MELD: Model for end-stage liver disease; OR: Odds ratio; CI: Confidence interval.

Table 4 Cox regression analyses of risk factors associated with 15-d mortality (dead: n = 13; alive: n = 22) in patients with spontaneous fungal peritonitis or fungiascites

	Univariate		Multivariate
	HR (95%CI)	P-value	HR (95%CI)	P-value
Age	0.959 (0.918-1.003)	0.066
Variceal bleeding	0.872 (0.285-2.666)	0.81
Hepatorenal syndrome	7.3 (2.216-24.435)	0.001	5.328 (1.050-18.900)	0.01
HE	2.654 (0.889-7.925)	0.08
Charlson index	1.155 (0.742-1.796)	0.523
WBC, 10⁹ cells/L	1.064 (1.009-1.122)	0.023	1.062 (0.933-1.137)	0.081
C-reactive protein, mg/L	1.003 (0.992-1.015)	0.564
INR	1.201 (0.520-2.776)	0.668
Total bilirubin, μmol/L	1.005 (1.003-1.008)	<0.001	1.005 (1.002-1.008)	0.002
Creatinine, μmol/L	1.010 (1.003-1.017)	0.005
Serum sodium, mmol/L	0.883 (0.814-0.958)	0.003	0.949 (0.867-1.039)	0.256
Concurrent bacterial infection	0.715 (0.240-2.129)	0.546
Anti-fungal therapy	0.758 (0.248-2.319)	0.627
SIRS	3.458 (0.948-12.611)	0.06
SOFA	1.305 (1.132-1.505)	<0.001
MELD	1.080 (1.021-1142)	0.008
CTP	1.727 (1.214-2.483)	0.002
APACHE II	1.113 (1.025-1.207)	0.01

HE: Hepatic encephalopathy; INR: International normalized rate; SIRS: Systemic inflammatory response; SOFA: Sequential organ failure assessment; APACHE II: Chronic liver failure-sequential organ failure assessment; MELD: Model for end-stage liver disease; CTP: Child-Turcotte-Pugh; OR: Odds ratio; CI: Confidence interval; HR: Hazard ratio.

Table 5 Performance of six prognostic scoring systems in predicting mortality in patients with spontaneous fungal peritonitis / fungiascites

Prognostic model	Auroc (95%CI)	Sensitivity (95%CI)	Specificity (95%CI)	Z score	P-value
SOFA	0.850 (0.707-0.993)	61.5 (31.8-86.1)	90.9 (70.8-98.9)
CLIF-SOFA	0.825 (0.686-0.964)	84.6 (54.6-98.1)	77.3 (54.6-92.2)	0.498	0.619
CTP	0.825 (0.675-0.975)	69.2 (38.6-90.9)	86.4 (65.1-97.1)	0.42	0.674
APPACHE II	0.722 (0.521-0.923)	61.5 (31.6-90.9)	86.4 (65.1-97.1)	1.335	0.182
MELD-Na	0.759 (0.556-0.962)	76.9 (46.2-95.0)	77.3 (54.6-92.2)	0.723	0.469
MELD	0.724 (0.514-0.934)	69.2 (38.6-90.9)	86.4 (65.1-97.1)	1.035	0.301
SIRS	0.680 (0.496-0.864)	76.9 (46.2-95.0)	59.1 (36.4-79.3)	1.429	0.153

SIRS: Systemic inflammatory response; SOFA: Sequential organ failure assessment; CLIF-SOFA: Chronic liver failure-sequential organ failure assessment; APACHE II: Chronic liver failure-sequential organ failure assessment; MELD: Model for end-stage liver disease; CTP: Child-Turcotte-Pugh.

Citation: Huang CH, Pang LT, Xu LC, Ge TT, Xu QM, Chen Z. Risk factors, clinical features, and short-term prognosis of spontaneous fungal peritonitis in cirrhosis: A matched case-control study. World J Clin Cases 2019; 7(17): 2438-2449
URL: https://www.wjgnet.com/2307-8960/full/v7/i17/2438.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i17.2438